Prescriptions And Market PerformanceTotal Auvelity prescriptions for 1Q25 reached ~167K, representing ~5% Q/Q growth, compared to a sequential decline in the overall antidepressant market of ~2%.
Product Launch And PipelineThe discussion highlighted the company's ongoing commercial progress with AUVELITY and Sunosi, as well as the rapidly approaching commercial launch of SYMBRAVO and the broad pipeline of additional assets spanning multiple neurology-focused indications.
Sales ProjectionsVisible Alpha consensus sales for 2025 are currently ~$480M, growing to ~$1B by 2027E.